Skip to main content
FDA OKs Akari's Coversin study for fatal pediatric disorder
3/14/2019

The FDA has signed off on Akari Therapeutics' endpoints for its pivotal study to assess Coversin to treat pediatric patients with hematopoietic stem cell transplant-related thrombotic microangiopathy. The trial is scheduled to launch in the last quarter of 2019.

Full Story: